文献速递核素与放射性配体治疗放射性药物与辐射防护

对氨基马尿酸联合输注在神经内分泌肿瘤患者肽受体放疗中肾脏保护的安全性与有效性

Safety and Efficacy of Para-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors.
PubMed 文献 · J Nucl Med · 2024-06-03

12例转移性或不可切除胃肠胰神经内分泌肿瘤患者接受177Lu-DOTATOC共33个治疗周期,其中15个周期联合输注8 g对氨基马尿酸(PAH),其余联合输注25 g精氨酸与25 g赖氨酸混合液(AA)。PAH组治疗前后平均肌酐、肾小球滤过率及血清电解质无变化(P≥0.20),AA组血清氯和血清磷显著升高(均P<0.01);PAH组肾脏吸收剂量系数为0.60±0.14 Gy/GBq,AA组为0.53±0.16 Gy/GBq。作者认为PAH是肽受体放疗中肾脏保护有前景的AA替代方案,需进一步研究不同PAH血浆浓度下的安全性和辐射剂量学。

要点

  • PAH组治疗前后平均肌酐、肾小球滤过率及血清电解质无变化(P≥0.20)。
  • AA组血清氯和血清磷显著升高(均P<0.01)。
  • PAH组肾脏吸收剂量系数0.60±0.14 Gy/GBq,AA组0.53±0.16 Gy/GBq。

核心结论

  • PAH是肽受体放疗中肾脏保护有前景的AA替代方案。
  • 需进一步研究系统探究不同PAH血浆浓度下的安全性和辐射剂量学。

研究设计与样本

  • 12例转移性或不可切除胃肠胰神经内分泌肿瘤患者接受177Lu-DOTATOC共33个治疗周期。
  • 共输注8 g PAH或25 g精氨酸与25 g赖氨酸混合液(AA)。
  • 安全性通过监测治疗前和治疗后24小时实验室数据(含血液学、肾脏数据及电解质)评估。
  • 辐射剂量学:全身扫描于1、24、48小时进行,SPECT/CT于48小时进行,血样于给药后5分钟及0.5、2、4、24、48小时采集。
  • 肾脏和骨髓吸收剂量按MIRD概念估算。

主要发现

  • 15个治疗周期共输注PAH。
  • PAH保护时,治疗前与治疗后24小时平均肌酐水平、肾小球滤过率和血清电解质无变化(P≥0.20)。
  • AA保护时,血清氯和血清磷显著升高(均P<0.01)。
  • 肾脏吸收剂量系数PAH组为0.60±0.14 Gy/GBq,AA组为0.53±0.16 Gy/GBq。
  • 基于外推4个周期的累积肾脏吸收剂量,本患者组中PAH保护1例和AA保护1例将超过23 Gy保守阈值。

关键数值与推荐

  • PAH组治疗前后平均肌酐、肾小球滤过率及血清电解质无变化(P≥0.20)。
  • AA组血清氯和血清磷显著升高(均P<0.01)。
  • 肾脏吸收剂量系数PAH组0.60±0.14 Gy/GBq vs AA组0.53±0.16 Gy/GBq。
  • 骨髓吸收剂量系数PAH组0.012±0.004 Gy/GBq vs AA组0.012±0.003 Gy/GBq。
  • 基于外推4个周期累积肾脏吸收剂量,PAH保护1例和AA保护1例将超过23 Gy保守阈值。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 需进一步研究系统探究不同PAH血浆浓度下的安全性和辐射剂量学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Para-aminohippurate, also known as p-aminohippuric acid (PAH), is used clinically to measure effective renal plasma flow. Preclinically, it was shown to reduce 177Lu-DOTATOC uptake in the kidneys while improving bioavailability compared with amino acid (AA) coinfusion. We report the safety and efficacy of PAH coinfusion during peptide receptor radiotherapy in patients with neuroendocrine tumors. Methods: Twelve patients with metastatic or unresectable gastroenteropancreatic neuroendocrine tumors received 177Lu-DOTATOC in 33 treatment cycles. Either 8 g of PAH or a mixture of 25 g of arginine and 25 g of lysine were coinfused. Safety was assessed by monitoring laboratory data, including hematologic and renal data, as well as electrolytes obtained before and 24 h after treatment. For radiation dosimetry, whole-body scans were performed at 1, 24, and 48 h and a SPECT/CT scan was performed at 48 h, along with blood sampling at 5 min and 0.5, 2, 4, 24, and 48 h after administration. Absorbed dose estimations for the kidneys and bone marrow were performed according to the MIRD concept. Results: In 15 treatment cycles, PAH was coinfused. No changes in mean creatinine level, glomerular filtration rate, and serum electrolytes were observed before or 24 h after treatment when using PAH protection (P ≥ 0.20), whereas serum chloride and serum phosphate increased significantly under AA (both P < 0.01). Kidney-absorbed dose coefficients were 0.60 ± 0.14 Gy/GBq with PAH and 0.53 ± 0.16 Gy/GBq with AA. Based on extrapolated cumulative kidney-absorbed doses for 4 cycles, 1 patient with PAH protection and 1 patient with AA protection in our patient group would exceed the 23-Gy conservative threshold. The bone marrow-absorbed dose coefficient was 0.012 ± 0.004 Gy/GBq with PAH and 0.012 ± 0.003 Gy/GBq with AA. Conclusion: PAH is a promising alternative to AA for renal protection during peptide receptor radiotherapy. Further research is required to systematically investigate the safety profile and radiation dosimetry at varying PAH plasma concentrations.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Moraitis A, Jentzen W, Fragoso Costa P, et al. Safety and Efficacy of Para-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors. J Nucl Med. 2024. PMID: 38637142. doi:10.2967/jnumed.123.266619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。